Speaker: Qingcong Lin, CEO, Biocytogen Boston Corporation
Date: Nov 3, 2022
Time: 12:20 PM CET/ 6:20 AM EDT
Next-Generation Humanized Models Accelerate Antibody Discovery, Lead Characterization & Candidate Selection
In this session, we will focus on NK Cell-based therapeutics, and will introduce several NK cell receptor humanized mouse models and tumor cell lines, as well as xenogeneic models that can be used to further accelerate lead characterization & selection of novel therapeutic antibodies and cell-based therapies (including CAR-NK). We'll also introduce the capability and advantages of multiple strains of fully human antibody transgenic mice, which have been generated to facilitate discovery of novel therapeutic mAbs, bispecific or multispecific antibodies, and TCR-like antibodies.
The Festival of Biologics brings together pharma & biotech, academics and research institutes, together with their partners across the value chain. Across antibodies, immunotherapy and biosimilars our participants share research, create new partnerships, and tackle the clinical trials, manufacturing and commercial challenges involved in bringing new therapies to market.
(Source: Festival of Biologics Basel 2022)
